公开(公告)号：US20200216416A1

公开(公告)日：2020-07-09

申请号：US16732733

申请日：2020-01-02

Applicant: Array BioPharma Inc.

Inventor： Adam Cook ,  Ronald Jay Hinklin ,  Oren T. McNulty

IPC: C07D401/14 ,  C07D405/14 ,  C07D413/14

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salts thereof, wherein X1, X2, X3, R1, R2, R3, R4, R5, R6 and R7 are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

公开(公告)号：US20190062330A1

公开(公告)日：2019-02-28

申请号：US16173726

申请日：2018-10-29

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Jay Bradford Fell ,  John P. Fischer ,  John J. Gaudino ,  Erik James Hicken ,  Ronald Jay Hinklin ,  Matthew Randolf Lee ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Henry J. Zecca

IPC: C07D471/04 ,  C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US09079890B2

公开(公告)日：2015-07-14

申请号：US14494430

申请日：2014-09-23

Applicant: Array BioPharma Inc.

Inventor： Thomas Daniel Aicher ,  Steven Armen Boyd ,  Mark Joseph Chicarelli ,  Kevin Ronald Condroski ,  Jay Bradford Fell ,  John P. Fischer ,  Indrani W. Gunawardana ,  Ronald Jay Hinklin ,  Ajay Singh ,  Timothy M. Turner ,  Eli M. Wallace

IPC: C07D417/00 ,  C07D401/14 ,  C07D417/14 ,  C07D213/75 ,  C07D417/12 ,  C07D401/12

CPC classification number: C07D401/14 ,  C07D213/75 ,  C07D401/12 ,  C07D417/12 ,  C07D417/14

Abstract: Provided are intermediates having the formulas wherein R2, R3, and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.

Abstract translation: 提供具有下式的中间体其中R2，R3和L如说明书中所定义，其可用于制备吡啶-2-基 - 氨基-1,2,4-噻二唑衍生物。

公开(公告)号：US20140256756A1

公开(公告)日：2014-09-11

申请号：US14355804

申请日：2012-10-30

Applicant: Array BioPharma Inc.

Inventor： Thomas Daniel Aicher ,  Josef Roland Benscik ,  Steven Armen Boyd ,  Kevin Ronald Condroski ,  Jay Bradford Fell ,  John Peter Fischer ,  Ronald Jay Hinklin ,  Scott Pratt ,  Ajay Singh ,  Timothy M. Turner

IPC: C07D417/14 ,  C07D413/14

CPC classification number: C07D417/14 ,  C07D413/14

Abstract: Compounds of Formula (I) and pharmaceutically acceptable salts thereof in which X1, X2, X3, L, R3, R4, R5, R7 and n have the meanings given in the specification, are modulators of GPR119 and are useful in the treatment or prevention of diseases such as, but not limited to, type 2 diabetes, diabetic complications, symptoms of diabetes, metabolic syndrome, obesity, dyslipidemia, and related conditions.

Abstract translation: 其中X1，X2，X3，L，R3，R4，R5，R7和n具有本说明书中给出的含义的式（I）化合物及其药学上可接受的盐是GPR119的调节剂，可用于治疗或预防 的疾病，例如但不限于2型糖尿病，糖尿病并发症，糖尿病症状，代谢综合征，肥胖症，血脂异常和相关病症。